Wanbury Quarterly Results
Wanbury quarterly results. In Mar 2025, Wanbury (WANBURY) reported revenue ₹174 Cr and net profit ₹20 Cr — revenue +4.8% YoY. Review Wanbury P/E valuation to evaluate earnings-based valuation against sector peers.
WANBURY Quarterly Results — Revenue, Profit & EPS Highlights
Wanbury latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Wanbury market cap to track the company's total market size over time.
- Revenue of ₹174 Cr in Mar 2025 (+6.1% vs Jun 2025, +4.8% vs Mar 2024)
- Net Profit of ₹20 Cr in Mar 2025 (+42.9% vs Jun 2025, -41.2% vs Mar 2024)
- EBITDA of ₹32 Cr in Mar 2025 (+28.0% vs Jun 2025)
- Operating Margin of 17.0% in Mar 2025 (+2.0pp vs Jun 2025)
- Earnings Per Share of ₹6.18 in Mar 2025 (+50.0% vs Jun 2025)
Wanbury Quarterly Results — Revenue, EBITDA, Net Profit & EPS
WANBURY quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | Jun 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 174 | 164 | 163 | 166 | 132 | 6.1% | 4.8% |
| Net Profit (₹ Cr) | 20 | 14 | 8 | 34 | 1 | - | - |
| EBITDA (₹ Cr) | 32 | 25 | 22 | 45 | 12 | - | - |
| EPS (₹) | 6.18 | 4.12 | 2.44 | 10.28 | 0.32 | - | - |
| Operating Margin (%) | 17.0% | 15.0% | 12.0% | 13.0% | 8.0% | - | - |
WANBURY Share Price Trend — 1-Year Movement Across Quarterly Results
Wanbury 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit WANBURY screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
WANBURY vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Wanbury latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 1971.4 | 1,823 | 282 | -10.5% | - | 15.5% | 381.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores